Drug intelligence / Profile preview

DYME

Development stage: Unknown
Modality: Small Molecules
Administration: Ophthalmic

Overview

DYME is an agent developed for use in cataract surgery. Its primary function is the selective staining of the anterior capsule, which facilitates continuous curvilinear capsulorhexis (CCC). It has also been included in developmental toxicity studies conducted through the National Toxicology Program.

Brand names: DYME
Other names: brilliant blue gBBG 250BBG250BBG-250Coomassie Brilliant Blue G-250

Beyond the preview

Go deeper on DYME.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DYME.

Explore the full profile